Status:

TERMINATED

Cell Therapy in Chronic Ischemic Heart Disease

Lead Sponsor:

Ministry of Health, Brazil

Collaborating Sponsors:

Ministry of Science and Technology

Conditions:

Ischemic Heart Disease

Coronary Artery Disease

Eligibility:

All Genders

30-75 years

Phase:

PHASE3

Brief Summary

This study was designed to test the hypothesis that direct injection of bone-marrow cells in the heart may increase the number of blood vessels, ameliorating the heart's performance, and relieving pat...

Detailed Description

Severe ischemic heart disease (IHD) remains a clinical challenge; many patients with IHD have undergone myocardial revascularization procedures (either percutaneous or surgical) but still remain sympt...

Eligibility Criteria

Inclusion

  • Diagnosis of chronic, severe, diffuse, multivessel atherosclerotic coronary artery disease (CAD) referred for CABG.
  • Echocardiogram-assessed LVEF between 25 and 55% (Simpson's rule).
  • Angina (or equivalent) functional class II to IV (Canadian Cardiovascular Society) despite maximally tolerated medical therapy.
  • Abnormal myocardial perfusion tests:
  • i. Cardiac scintigraphy ii. Magnetic resonance imaging iii. Dobutamine-atropine stress-echocardiogram
  • Non-candidates for a percutaneous coronary intervention (PCI) due to ANY of the following:
  • i. High risk lesion ii. Extensive lesion iii. Diffuse, small vessel disease
  • Non-candidates for a complete CABG, or candidates for a complete CABG in whom, according to an expert panel, there is a high probability of failure of the grafts due to the extension and severity of the disease, with diffuse, small vessel involvement.
  • To provide a signed, written informed consent, according to the National Guidelines for Clinical Trials.

Exclusion

  • Severe valve heart disease requiring surgical repair.
  • Serologic diagnostic of Chagas' disease.
  • Symptoms of heart failure, even from an ischemic etiology, in the absence of objectively documented myocardial ischemia.
  • Malignant ventricular arrhythmias (like VT), unless an ICD have been placed.
  • Any acute coronary syndrome in the past 3 months.
  • End-stage renal disease requiring maintenance dialysis.
  • History of neoplasia.
  • Drug or alcohol abuse.
  • Life expectancy below 2 years.
  • Enrollment in any cell therapy trial in the past 2 years.

Key Trial Info

Start Date :

January 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2008

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT00362388

Start Date

January 1 2006

End Date

November 1 2008

Last Update

January 27 2010

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Irmandade da Santa Casa de Misericórdia

Curitiba, Paraná, Brazil, 80010-030

2

Clínica Cardiologyca C. Constantini

Curitiba, Paraná, Brazil, 80320-320

3

Instituto do Coração de Pernambuco do Real Hospital Português de Beneficência

Recife, Pernambuco, Brazil, 52010-040

4

Instituto Nacional de Cardiologia Laranjeiras (INCL)

Rio de Janeiro, Rio de Janeiro, Brazil, 22240-002